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BACKGROUND: CD70 is an ideal target for antibody-based therapies because of its aberrant high expression in renal carcinomas and
non-Hodgkin lymphomas and its highly restricted expression in normal tissues. The expression profiling of CD70 in carcinomas has
been limited because of the lack of a CD70-specific reagent that works in formalin-fixed paraffin-embedded (FFPE) tissues.
METHODS: We generated murine monoclonal antibodies (mAbs) specific for CD70 and validated their specificity by western blot
analysis and developed a protocol for immunohistochemistry on FFPE tissues. CD70þ tumour cell lines were used for testing the
anti-tumour activity of the anti-CD70 antibody–drug conjugate, SGN-75.
RESULTS: We report novel detection of CD70 expression in multiple cancers including pancreatic (25%), larynx/pharynx (22%),
melanoma (16%), ovarian (15%), lung (10%), and colon (9%). Our results show that pancreatic and ovarian tumour cell lines, which
express high levels of endogenous or transfected CD70, are sensitive to the anti-tumour activity of SGN-75 in vitro and in vivo.
CONCLUSION: Development of murine mAbs for robust and extensive screening of FFPE samples coupled with the detection of
anti-tumour activity in novel indications provide rationale for expanding the application of SGN-75 for the treatment of multiple
CD70 expressing cancers.
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Pancreatic cancer is the fourth leading cause of cancer death
among men and women in the United States. In 2009, it was
estimated that 42470 individuals in the US will be diagnosed with
pancreatic cancer and over 35240 will die from the disease (Jemal
et al, 2009). The 5-year relative survival rate for pancreatic cancer
is only 5.1% and it has changed little in the last three decades. For
ovarian cancer, 21550 women will be diagnosed in 2009 and 14600
women will die of the disease (Jemal et al, 2009). The overall 5-year
relative survival rate was 45.5% for 1996–2004. Worldwide,
around 140000 women die of ovarian cancer every year (National
Cancer Institute SEER Cancer Statistics). Both ovarian and
pancreatic cancer patients have great unmet need for better
therapeutic options.
CD70 (TNFSF7), a member of the tumour necrosis factor (TNF)
superfamily, is a type II integral membrane protein and the ligand
for CD27 (Goodwin et al, 1993; Bowman et al, 1994; Hintzen et al,
1994b). CD70 is transiently expressed in antigen-activated T and B
lymphocytes (Hintzen et al, 1994a, 1995; Lens et al, 1996) and its
interaction with CD27 regulates T- and B-cell functions (Jacquot
et al, 1997; Agematsu et al, 1998; Hendriks et al, 2000; Arens et al,
2001; Tesselaar et al, 2003; Xiao et al, 2004). CD70 protein
expression is very limited in non-lymphoid organs and has been
reported only in stromal cells of the thymic medulla (Hishima
et al, 2000) and mature dendritic cells (Bullock and Yagita, 2005).
Aberrant expression of CD70 in solid tumours and haematologic
malignancies has also been described by various studies
(Agathanggelou et al, 1995; Lens et al, 1999; Diegmann et al,
2005; Law et al, 2006). CD70 has been reported to be highly
expressed in renal cell (clear and papillary types) (Law et al, 2006),
thymic (Hishima et al, 2000), nasopharyngeal (Agathanggelou
et al, 1995), and brain (astrocytoma, glioblastoma) tumours
(Wischhusen et al, 2002). It is also widely expressed in Hodgkin
and non-Hodgkin lymphomas (HL and NHL), Waldenstrom’s
macroglobulinemia, chronic lymphocytic leukaemia, and multiple
myeloma (MM) (Al Saati et al, 1989; Ranheim et al, 1995; Treon
et al, 2007; McEarchern et al, 2008).
We have previously shown targeting CD70 in renal cell carci-
nomas (clear cell and papillary types) and in haematologic
malignancies (HL, MM) using anti-CD70-drug conjugates
(Law et al, 2006; Oflazoglu et al, 2008; Alley et al, 2009). Both
chimeric and humanised anti-CD70 monoclonal antibody (mAb)
1F6 conjugated to a microtubule-disrupting auristatin have been
shown to be active in these tumours. With the limited normal
tissue distribution, aberrant expression in tumours, and cell
surface expression with no observed shedding of the antigen, CD70
is an attractive target for antibody–drug conjugate (ADC)-based
therapy. The ADCs generated against CD30 (brentuximab vedotin
(SGN-35)) and erbB2 (Herceptin-DM1) are currently in clinical
trials with tumour reductions and minimal toxicity observed
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s(Senter, 2009). The clinical potential of empowered antibodies has
heightened the pursuit of ADCs for additional targets and tumour
indications. SGN-75, an auristatin-based anti-CD70 ADC, recently
entered a phase I clinical trial for patients with renal cell carcinoma
and NHL. In this study, we expanded our analysis of CD70
expression in various types of carcinomas to identify new potential
indications for SGN-75.
MATERIALS AND METHODS
Reagents and cell lines
Peroxidase-conjugated and Cy5-conjugated goat anti-mouse IgG
were purchased from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA). 3,30,5,50-Tetramethylbenzidine was
purchased from Pierce (Rockford, IL, USA). Basal media,
penicillin, streptomycin, FBS and sodium hypoxanthine, aminop-
terin and thymidine (HAT) were purchased from Invitrogen
(Carlsbad, CA, USA). Cloning factor and complete mini-protease
inhibitors were from Roche Diagnostics (Indianapolis, IN, USA),
and fetal clone I was from Hyclone (Logan, UT, USA). Pancreatic
(Capan-1, Capan-2, SU.86.86, Panc-1, HPAF-II, MiaPaCa-2),
ovarian (OVCAR-3, SK-OV-3, CaOV3, TOV-21G), endometrial
(AN3CA), renal (786-O), and colon (NCI-H716) carcinoma cell
lines were obtained from American Tissue Culture Collection
(ATCC, Manassas, VA, USA). All cell lines were grown in culture at
371C using recommended cell culture media according to ATCC.
Recombinant CD70 purification
Chinese hamster ovary DG44 cells were transfected with a
construct encoding the cynomolgus CD70 (cyno CD70) extra-
cellular domain (ECD) with a FLAG tag and the soluble
recombinant protein was harvested from the media. The cynoCD70
ECD was purified by affinity and size-exclusion chromatography
using an A ¨KTA explorer FPLC (GE Healthcare, Piscataway, NJ,
USA). Briefly, the media were concentrated and treated with 0.05%
(v/v) Tween-20, 0.25% Triton X-100 (Sigma, St Louis, MO, USA).
Samples were loaded on to M2 anti-FLAG affinity column (GE
Healthcare). FLAG cynoCD70 was then eluted from the column
with 0.1M glycine, pH 3.5 and then dialysed against PBS, pH7.4.
The pooled protein was then loaded on to Superdex 200 (GE
Healthcare) pre-equilibrated with PBS, pH 7.4 to remove low
molecular weight contaminants.
Antibody generation
Female BALB/c mice were immunised subcutaneously with
denatured recombinant CD70 ECD using TiterMax adjuvant
(Sigma). B cells were harvested from immunised spleens and
fused to P3-X63.Ag8 myeloma cells using a standard PEG fusion
protocol (Goding, 1996). Hybridomas were cultured in 80% IMDM
with 4mmoll
 1 L-glutamine, 10% fetal clone I, 10% cloning
factor supplemented with penicillin, streptomycin and 1  HAT.
Hybridoma culture supernatants were tested for binding to
purified recombinant CD70 protein by ELISA and for binding to
formalin-fixed CD70-positive cells using a FMAT8200 instrument
(Applied Biosystems, Foster City, CA, USA). Positive hybridomas
were then screened on formalin-fixed paraffin-embedded (FFPE)
cell pellets to identify hybridomas that react with denatured CD70
for immunohistochemistry (IHC) analysis. The top two hybrido-
mas, designated SG-21.1C1 and SG-21.5D12, were cloned in semi-
solid media using a ClonePixFL instrument (Genetix, New Milton,
Hampshire, UK) and then expanded for purification. Antibodies
were affinity purified using Mabselect Sure resin (Amersham,
Piscataway, NJ, USA), eluted using 25mM acetate (pH¼3.4) and
dialysed in PBS.
ELISA and cell-based binding assays
Immunosorb 96-well plates were coated with 2mgml
 1 of
recombinant cynoCD70, washed with PBSþ1% Tween (PBS-T),
and blocked with PBS-T plus 1% (w/v) BSA. CD70-coated plates
were incubated with hybridoma culture supernatants for 2h at
room temperature (RT), washed 5  with PBS-T, and incubated
with peroxidase conjugated goat-anti-mouse IgG. After incubation
with secondary antibody, plates were washed, incubated with
3,30,5,50-tetramethylbenzidine substrate, and stopped with an
equal volume of 1moll
 1 H2S04. For cell-based binding assays,
HEK 293:pcDNA and HEK 293:cynoCD70-transfected cell lines
were plated at a density of 20000 cells per well in black 96-well
plates (Applied Biosystems). Hybridoma culture supernatants
were added to wells at 1/10th volume and supplemented
with 100ngml
 1 of Cy5-conjugated goat-anti-mouse IgG. Test
wells that differentially bound to HEK 293:cynoCD70 but not
HEK 293:pcDNA were ranked using a FMAT8200 instrument
(Applied Biosystems).
Membrane preparation and western blot analysis
Harvested cells were resuspended in hypotonic lysis buffer (10mM
Tris, pH 7.4, 10mM KCl, 1.5mM MgCl2)w i t h1 m M DTT plus
protease inhibitors and cell membranes were disrupted using a
dounce homogeniser. Nuclei were pelleted by centrifugation at
10000 g for 30min. The supernatant was collected and membrane
fractions were pelleted by centrifugation at 100000 g for 30min
and then solubilised in NP40 lysis buffer (0.5% NP40, 50mM Tris,
pH 8.0, 150mM NaCl, 5mM EDTA) containing protease inhibitors.
Purified FLAG-CD70 ECD and membrane preps of HEK 293F, HEK
293F/cynoCD70, and 786-O cells were run on a 4–20% gradient
Tris-Glycine gel (Life Technologies, Carlsbad, CA, USA) under
reducing conditions and transferred to PVDF membrane. For
western blot analysis, membranes were first blocked in PBS-Tþ1%
BSA and then incubated with 0.5mgml
 1 of purified SG-21.1C1 or
SG-21.5D12 in PBS-Tþ1% BSA at RT for 1h. A rabbit polyclonal
antibody against b-actin (Cell Signaling, Danvers, MA, USA) was
used as protein loading control. The blots were washed, incubated
with HRP-conjugated anti-mouse IgG and then washed and
developed using the West Pico ECL reagent (Pierce/Thermo Fisher
Scientific, Rockford, IL, USA).
Immunohistochemistry
Tumour microarrays (TMAs) and normal tissue microarrays were
obtained from a commercial source (USBiomax Inc., Rockville,
MD, USA). Formalin-fixed cells spun down into pellets and
paraffin-embedded, FFPE tissue samples or TMAs sectioned on
glass slides were deparaffinised and rehydrated. EDTA-based
antigen retrieval was carried out at 95–991C for 40min before
incubation with the primary antibodies (1mgml
 1 for 30–45min
at 251C). Isotype-matched murine antibodies (Sigma) were used as
negative controls for background staining. For manual staining, an
anti-murine secondary antibody conjugated to HRP was used with
detection using diaminobenzidine (DAB) as chromogen. For
automated staining, either Refine DAB Kit or Alkaline Phospha-
tase-Red was used with the BondmaX autostainer (Leica Micro-
systems, Bannockburn, IL, USA) for detection of primary antibody
binding. Tissue microarray slides were analysed and scored by a
pathologist and images were taken using Zeiss Axiovert 200M
microscope (Carl Zeiss, Inc., Thornwood, NY, USA).
Flow cytometric analysis
Cells were incubated for 30min on ice with PE-conjugated murine
anti-CD70 antibodies (BD Pharmingen, San Diego, CA, USA),
washed with cold staining medium, and evaluated with a Becton
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number on the cell surfaces was determined using a murine anti-
CD70 mAb (Ki-24, BD Pharmingen) and the DAKO QiFiKit flow
cytometric indirect assay as described by the manufacturer (DAKO
A/S, Glostrup, Denmark).
Detection of human CD70 expression by PCR
The expression of human CD70 in pancreatic carcinoma was
examined by PCR with cDNA preparations obtained from tumour
tissues. Primers that spanned the coding regions (exons 1 to 3) for
TNFSF7 and to amplify the housekeeping gene, GAPDH, were
synthesised by Operon Biotechnology (Huntsville, AL, USA).
Human GAPDH –5 0-CCACCCATTGGCAAATTCCATGGCA-30
(forward) and 50-TCTAGACGGCAGGTCAGGTCCACC-30 (reverse).
Human TNFSF7 –5 0-GCTGGTCCCCTGACAGGTTGAA-30 (for-
ward) and 50-CCTTCTCTTGTCCTGCCACCAC-30 (reverse).
PCR was carried out in an Eppendorf Mastercycler (Westbury,
NY, USA) with 1ml cDNA and 200nM primers. The samples were
heated for 5min at 941C and then one group was used to amplify
CD70 (941C for 45s, 621C for 45s, and 721C for 45s for 35 cycles
followed by an incubation at 721C for 5min to yield a product of
852bp), whereas the other was used for GAPDH (941C for 45s,
691C for 45s, and 721C for 45s for 23 cycles followed by an
incubation at 721C for 5min to yield a product of 580bp). PCR
products were visualised by electrophoresis on a 1% agarose gel.
The identities of the PCR products were confirmed by sequencing.
Cytotoxicity assay
Tumour cells were incubated with h1F6 (anti-CD70 mAb) and
h1F6-mcMMAF drug conjugate (SGN-75) for 96h at 371C. A non-
binding ADC (cAC10-mcMMAF) was used as a negative control.
Cell viability was measured by CelltiterGlo (Promega Corporation,
Madison, WI, USA) according to the manufacturer’s instructions.
Cells were incubated for 25min at room temperature with the
CellTiter-Glo reagents and luminescence was measured on a
Fusion HT fluorescent plate reader (Perkin Elmer, Waltham, MA,
USA). Results are reported as IC50, the concentration of compound
needed to yield a 50% reduction in viability compared with
vehicle-treated cells (control¼100%).
Generation of stable pancreatic cell line expressing CD70
A full-length cynomolgus gene for TNFSF7, previously isolated for
non-human primate binding studies, was used to create stable
HEK 293F and MiaPaCa-2 transfectants for antibody screening and
in vivo studies, respectively. The cynomolgus TNFSF7 gene is
490% homologous to human TNFSF7 (based on sequencing) and
SGN-75 binds with the same affinity to cyno CD70 and human
CD70 (unpublished data). The pancreatic cell line MiaPaCa-2 was
transfected with 1mg of linearised pcDNA3.1-cynoCD70 plasmid
using Lipofectamine 2000 reagent (Life Technologies) in six-well
tissue culture plates according to the manufacturer’s protocol.
Transfection media was replaced with selective media containing
800mgml
 1 of Geneticin (Life Technologies) 24h after transfec-
tion. Media was replaced every 2–3 days until the outgrowth of
positive transfectants. The cell surface expression of CD70 was
then assessed by flow cytometry. CD70-positive bulk cultures were
cloned by limiting dilution cloning and grown for at least 4 weeks
in growth media without selective antibiotic to identify CD70-
positive stable clones.
In vivo activity study
Nude (nu/nu) female mice (seven animals per group) were implan-
ted with MiaPaCa-2/CD70 tumour pieces by trocar into the right
lateral flank. Dosing with either SGN-75 or non-binding control
ADC (3mgkg
 1) started when tumours reached 100mm
3 (four
intraperitoneal injections at 4-day interval). Tumour volumes were
monitored using calipers and animals were euthanised when
tumour volume reached B800mm
3. Median tumour volume plots
were continued for each group until one or more animals were
killed. Kaplan–Meier curves were generated to reflect survival of
each animal per group and statistical analysis was carried out
using Log-rank (Mantel–Cox) test (GraphPad Prism, GraphPad
Software, San Diego, CA, UAS). All animal procedures were carried
out under a protocol approved by the Institutional Animal Care
and Use Committee in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care.
RESULTS
Validation of anti-CD70 mAb as an IHC reagent
Profiling of CD70 across a broad array of tumour samples has been
limited by the lack of an available antibody that reacts specifically
with CD70 in FFPE tissues. Our testing of commercially available
anti-CD70 mAbs as well as rabbit polyclonal antibodies generated
against various CD70 peptides showed either non-specific binding
or no binding at all in FFPE tissues (data not shown). Therefore,
we embarked on a de novo antibody campaign to develop a high-
quality IHC reagent for detection of CD70 in normal and
pathologic tissue samples. Screening of a panel of anti-CD70
hybridomas by IHC using FFPE CD70þ and CD70  cell pellets
identified two hybridomas that showed selective binding to
CD70þ cells. These hybridomas, designated 1C1 and 5D12, were
then cloned and purified for further characterisation.
The specific binding of mAbs 1C1 and 5D12 to CD70 was
analysed by western blot analysis using purified FLAG-tagged
CD70 ECD and membrane-enriched samples from HEK 293F
parental, CD70-transfected HEK 293F cells and a CD70þ renal cell
carcinoma cell line (786-O). Figure 1A shows that both mAbs
bound to the purified CD70 ECD (lanes 1 and 5) and to three
distinct bands from the CD70þ membrane preps (lanes 3, 4, 7,
and 8). No binding was observed in extracts from parental 293 cells
as expected (lane 2 and 6). CD70 is predicted to be trimeric based
on its structural homology to TNF-a. The three distinct bands
detected in membrane extracts of CD70 transfected cells (lanes 3
and 7) are identical to the endogenous CD70 expressed by 786-0
cells (lanes 4 and 8). The molecular sizes of 29kDa, 55–60kDa,
and 495kDa are remarkably similar to the pattern described by
Lens et al (1999) when 2 other anti-CD70 mAbs were used for
immunoprecipitation studies. We used b-actin as loading control
for the cell lysates (Figure 1A, lower panel).
IHC analysis on normal tissue microarrays
To further test the specificity of the two mAbs for binding to CD70,
we carried out IHC analysis on a FFPE tissue microarray of normal
human tissues containing at least three different individual cores
for each tissue type. As shown in Figure 1B, positive staining was
restricted to lymphoid tissues (tonsil, thymus, spleen), and gut-
associated lymphoid cells (data not shown) in which activated
CD70þ lymphocytes can be found. Normal vital organs such as
kidney, pancreas, and liver are negative (Figure 1B). The restricted
binding of mAb 1C1 and mAb 5D12 in normal tissues microarrays
and western blot analysis contrasted with testing of commercially
available CD70 antibodies which gave non-specific binding in
CD70-negative cells and tissues (data not shown).
FACS analysis
To confirm the IHC data, we performed quantitative fluorescence
activated cell sorting (qFACS) on various pancreatic and ovarian
cancer cell lines using an anti-CD70 mAb that is different from 1C1
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surface expression, wheraes IHC will capture both membrane and
intracellular CD70 protein expression. Results are shown in Table 1
and Figure 2. In vitro, the ovarian cancer cell line SK-OV-3 had the
highest level of CD70 detected by qFACS (2.2 10
5 antigens per
cell), whereas the Panc-1 cell line had 1 10
4 antigens per cell.
Reverse trancriptase–PCR analysis for CD70 expression also
showed that SK-OV-3 cells have relatively higher level of CD70
mRNA compared with Panc-1 and TOV-21G cells (Figure 2C).
There was a good correlation for detection of CD70 expression
levels using three assays (reverse trancriptase–PCR, flow cyto-
metry, and IHC). With the exception of the Panc-1 cell line, four
out of the five pancreatic cell lines analysed were negative for CD70
transcript and protein expression.
Thymus Spleen Tonsil
Pancreas Liver
1C1 5D12
12
98
*
*
*
64
50
36
22
-Actin
34 5678
Kidney
Figure 1 Characterisation of anti-CD70 1C1 and 5D12. (A) Western blots containing FLAG-tagged CD70 ECD (lanes 1 and 5) and membrane extracts
from HEK 293 cells (lanes 2 and 6), HEK 293:CD70 transfectants (lanes 3 and 7) and 786-O cells (lanes 4 and 8) were reacted with mAb 1C1 (left panel) or
mAb 5D12 (right panel). The mAb 1C1 and 5D12 specifically bound recombinant CD70 (lane 1 and 4) and three distinct bands (*) from CD70þ
membrane extracts (lanes 3, 4, 7, and 8). Extracts from parental HEK 293 cells were negative as expected (lane 2 and 6). The b-actin control shows
comparable quantities of protein were loaded for each membrane extract (lower panels). (B) IHC analysis on FFPE normal human tissues showing limited
expression of CD70 in lymphoid tissues. Red stain indicates presence of CD70þ cells. 1C1 mAb was used for these set of images.  400 magnification,
scale bar¼50mm.
Table 1 Comparative CD70 expression in pancreatic and ovarian cancer cell lines by immunohistochemistry and quantitative FACS
Cell line Tumor type CD70 IHC (1C1) CD70 IHC (5D12) CD70 receptor number
a ( 10
3)
OVCAR-3 Ovarian 1+ 1–2+ 1.3
SK-OV-3 Ovarian 3+ 3+ 223
CaOV3 Ovarian 1+ 2+ 0.3
TOV-21G Ovarian 1+ 1+ 2
CAPAN-1 Pancreatic Negative Negative 0
CAPAN-2 Pancreatic Negative Negative 0
SU86.86 Pancreatic Negative Negative 0
Panc-1 Pancreatic 2+ 2+ 10
HPAF-II Pancreatic Negative Negative 0
MiaPaCa-2/CD70 Pancreatic CD70 transfectant 3+ ND
b 366
Abbreviations: IHC¼immunohistochemistry; ND¼not determined.
aDetermined by quantitative FACs.
bNo data.
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We proceeded to use 1C1 and 5D12 mAbs as IHC reagents to
expand our analysis of CD70 expression in various tumour types.
We have previously reported finding CD70 expression in about
70% of renal cell carcinoma cases (Law et al, 2006). More recently,
we also reported on expression of CD70 in other haematologic
tumour types (McEarchern et al, 2008). Table 2 summarises the
results from our analysis of various TMAs. Notably, we observed
novel aberrant expression of CD70 in multiple solid tumour types,
such as pancreatic (35 out of 140), melanoma (15 out of 96),
ovarian carcinomas (37 out of 241), and lung adenocarcinomas
(17 out of 172). Most of the melanoma cases have low intensity
(1–2þ) and a low percentage (1–50%) of CD70þ tumour cells.
Our data also confirms high expression of CD70 (70%) in most but
not all of renal cell carcinoma cases, consistent with our earlier
study using another anti-CD70 mAb (1F6) in frozen tissue
microarrays (Law et al, 2006). We did observe a lower percentage
of CD70-positive cases in nasopharyngeal and brain cancers
compared with previously published studies. Our analysis showed
18 out of 82 cases of laryngeal and pharyngeal cancers are positive
for CD70 (Table 2), whereas Agathanggelou et al (1995) reported
that 16 out of 20 nasopharyngeal cancers were CD70 positive. We
also found CD70-positive staining in only 6 out of 59 cases of brain
cancers. In contrast, Wischhusen et al (2002) found that 5 out of 12
glioblastomas and 3 out of 4 anaplastic astrocytomas were positive
for CD70 protein.
As shown in Figure 3, the intensity and pattern of CD70
expression in these tumours are highly variable. To describe the
variability of expression, we plotted the intensity of CD70 staining
against the percentage of tumour cells that stained positive within
the biopsy core (Figure 3A and B). For both pancreatic and ovarian
tumours, about 14% of all cases showed 3–4þ staining intensity.
In contrast, just 1.6% of ovarian cases showed a lower staining
intensity of 1–2þ, whereas 11% of all pancreatic cases had an
intensity of 1–2þ (Figure 3B). CD70þ renal cell carcinomas
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Figure 2 Correlation of CD70 expression in cell lines by qFACS, IHC, and reverse trancriptase–PCR: (A) Quantitative flow cytometric analyses were
carried out on ovarian (SK-OV-3, TOV-21G), and pancreatic (Panc-1) cell lines using a PE-conjugate murine anti-CD70 ab (BD Pharmingen). CD70 copy
number was determined using standard labelled bead controls (QiFiKit, DAKO). (B) Corresponding cell pellets were harvested and processed as FFPE
samples and immunohistochemistry using 1C1 (as shown) or 5D12 was carried out using alkaline phosphatase-labelled secondary antibody and Fast Red as
the chromogen. Images were taken using a Zeiss microscope at 400  magnification. Scale bar¼50mm. (C) Detection of human CD70 expression by
reverse trancriptase–PCR: expression of CD70 in various CD70þ cell lines was determined using cDNA preparations obtained from the cells (lanes 1:
AN3CA ovarian; 2: SKOV-3 ovarian; 3: TOV-21G ovarian; 4: NCI-H716 colorectal; 5: 786-O renal; 6: PANC-1 pancreatic; 7: IGROV-1 ovarian (CD70
negative); 8: H2O). Primers that partially spanned the coding regions were used for CD70. PCR products were sequenced to confirm their identity. hCD70
(TNFSF7) fragment¼852bp, including exons 1,2, and 3. Human GAPDH (hGAPDH) (580bp) was used as housekeeping gene PCR control.
Table 2 Summary of CD70 expression from tissue microarray analysis
of carcinomas using 1C1
Tumor type CD70+ of total %CD70+
Kidney
a 204 of 283 72
Pancreas 35 of 140 25
Larynx or pharynx
b 18 of 82 22
Melanoma 15 of 96 16
Ovary 37 of 241 15
Lung adenocarcinoma 17 of 172 10
Colon 17 of 194 9
Breast 5 of 204 2
Brain 6 of 59 10
a189 of 230 (82%) clear cell carcinoma and 4 of 8 (50%) papillary carcinoma.
bIncludes nasopharyngeal cancer.
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(3–4þ, data not shown). CD70 was not detected in the normal
pancreas and ovary samples tested. Other tumour types that
expressed CD70 (Table 2) also showed heterogeneous staining
pattern with lower intensity. In a number of cases, we also
observed infiltrating leukocytes within the tumours that were
CD70þ (data not shown).
In vitro activity of SGN-75 against CD70þ ovarian and
pancreatic cell lines
We have previously reported that mAb-drug conjugates (ADC)
targeting CD70 on the cell surface deliver a highly potent cytotoxic
antitubulin agent, monomethyl auristatin F (MMAF). This anti-
CD70 ADC, designated as SGN-75, is a humanised mAb (h1F6) that
has an average of four drugs (MMAF) attached by a maleimido-
caproyl (mc) linker (h1F6-mcMMAF(4)) (Oflazoglu et al, 2008).
On internalisation of the ADC, the drug cys-mcMMAF is released
(Alley et al, 2009), resulting in disrupted tubulin polymerisation
and apoptosis. To determine whether SGN-75 can inhibit the
growth of ovarian and pancreatic cancer cells, we carried out in
vitro cytoxicity assays using ovarian cancer cell lines SK-OV-3 and
TOV-21G and a pancreatic cancer cell line Panc-1. In the ovarian
cell line SK-OV-3, SGN-75 induced dose-dependent cytotoxicity
that is specific with an IC50¼29ngml
 1 (Figure 4A). Unconju-
gated 1F6 had no effect, whereas the non-binding
ADC control showed some cell killing but only at the highest
doses tested (41000ngml
 1,I C 50¼3400ngml
 1), suggesting
that specific cell killing was mediated by SGN-75 subsequent to
its binding to CD70.
Pancreas tumours
35/140 (25%) = CD70 positive
5 6
2
3
75
100
0
25
50
012345
%
 
A
r
e
a
 
p
o
s
i
t
i
v
e
Staining intensity
Ovarian tumours
37/241 (15%) = CD70 positive
4
1
2
10
%
 
A
r
e
a
 
p
o
s
i
t
i
v
e
100
25
50
75
0
Staining intensity
2 3 1
1 1
5 3 3
05 4 3 2 1
5
5
6
3 1
Figure 3 Immunohistochemistry analysis using anti-CD70 mAb (1C1) in tumour microarrays. CD70 expression in pancreatic (A) and ovarian
(B) tumours is shown. Of the 140 and 241 individual cases of pancreatic and ovarian carcinoma, respectively, 35 cases (25%) and 37 cases (15%) were found
to be CD70þ. In this analysis, the area of transformed cells within each biopsy stained positively for CD70 expression is categorised into o25%, 25–50%,
50–75%, and 475%. The intensity of CD70 expression is expressed as: 1¼weak, 2¼mild, 3¼moderate, 4¼strong ( 400 magnification). To illustrate
the heterogeneity in CD70 expression, the percent area positive is plotted against staining intensity. In these plots, the number in each in the graphs denotes
the number of CD70þ cases. Representative images for low, heterogeneous (25–50% positive, 2þ) and high, homogeneous (475% positive, 4þ) CD70
for pancreatic and ovarian carcinoma are shown.
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cells or the pancreatic cell line Panc-1 (data not shown) possibly
because of the relatively low level of CD70 expression found on
these cells when compared with SK-OV-3 cells (Table 1). Hence,
validating the anti-tumour activity of SGN-75 on pancreatic cell
lines presented a challenge because within the panel of pancreatic
cell lines studied, only Panc-1 cells express CD70 (Table 1). To
overcome this obstacle, we engineered another pancreatic cell line
MiaPaCa-2 to express CD70 (designated as MiaPaCa-2/CD70).
MiaPaCa-2/CD70 is a stable cell line that expressed high levels
of CD70 as determined by qFACs (Table 1). MiaPaCa-2/CD70
cells were effectively killed by SGN-75 in vitro with an
IC50¼29ngml
 1, whereas the parental cell line that lacked CD70
was unaffected (Figure 4B). Taken together, these in vitro studies
showed that SGN-75 has the potential to kill ovarian and
pancreatic cancer cell lines that express moderate to high levels
of CD70.
In vivo activity of SGN-75 against MiaPaCa-2/CD70
Next, we tested the anti-tumour activity of SGN-75 in vivo using
CD70þ tumour xenografts. Model development with SK-OV-3
revealed that expression of CD70 was significantly down modu-
lated in subcutaneous tumour xenografts with a lack of consistency
between tumour samples (data not shown). For this reason, we
used MiaPaCa-2/CD70 which retained high expression of CD70
in vivo. Mice were dosed with either 3mgkg
 1 of SGN-75 or a non-
binding control ADC every 4 days for a total of four doses starting
when tumour volumes reached 100mm
3. Administration of
SGN-75 significantly reduced median tumour volumes and delayed
tumour growth when compared with untreated controls or a non-
binding ADC (Figure 4C). SGN-75 treated mice also showed statis-
tically significant prolonged survival (median survival of 60 days)
compared with either untreated control group (30 days) or non-
binding ADC (32 days) (P¼0.01) (Figure 4D), thus confirming the
MiaPaCa-2 CD70 transfectant
MiaPaCa-2 SGN-75
Non-binding ADC
SK-OV-3
%
 
o
f
 
u
n
t
r
e
a
t
e
d
%
 
o
f
 
c
o
n
t
r
o
l
IC50:
SGN-75: 29 ng ml–1
0.1 1
10
100
1000
10 000
100 000
100
120
40
60
80
0
20 IC50=29 ng ml–1
0.001
0.01
0.1 1
10
100
1000
10 000
100
120
40
60
80
0
20 Non-binding ADC:
3400 ng ml–1
[ADC], ng ml–1 [Antibody or ADC], ng ml–1
Untreated
SGN-75 3 mg kg–1
Non-binding ADC 3 mg kg–1
600
400
500
200
300
0
100
M
e
d
i
a
n
 
t
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
Dosing
5 1 01 52 02 53 03 54 0 0
Days post tumour implant
Untreated
SGN-75 3 mg kg–1
Non-binding ADC 3 mg kg–1
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
0 2 04 06 08 0 1 0 0
120
80
100
20
40
60
0
P=0.01
Days taken to reach 800 mm
3
h1F6
Figure 4 In vitro and In vivo Anti-tumour Activity of SGN-75: (A and B) In vitro cytotoxicity assay showing potency of SGN-75 (triangles) on SK-OV-3
ovarian and CD70-transfected MiaPaCa-2 pancreatic carcinoma cell lines. The controls, unconjugated h1F6 control ( )a n dn o n - b i n d i n gA D C( A, squares)
have no effect. IC50 for SGN-75 and non-binding ADC are noted. Similarly, no cytotoxicity is observed in the untransfected MiaPaCa-2 control (B, squares).
(C and D) In vivo anti-tumour activity of SGN-75 in CD70-transfected MiaPaCa-2 pancreatic carcinoma tumours in nude mice. Mice treated with SGN-75
(squares) showed a significantly reduced median tumour volume (C) and a higher percent survival (D) when compared with untreated (circles) and
non-binding ADC (triangles).
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out of seven mice, in which the tumours completely regressed with
SGN-75 treatment.
DISCUSSION
CD70 is a rapidly internalising cell surface antigen that shows a
minimal expression on normal tissue but is frequently upregulated
on haematologic malignancies (Al Saati et al, 1989; Lens et al, 1999;
McEarchern et al, 2007), nasopharygeal carcinomas (Agathangge-
lou et al, 1995), and renal cell carcinomas (Junker et al, 2005;
Diegmann et al, 2006; Law et al, 2006). These qualities make CD70
an attractive therapeutic target for an anti-CD70 ADC. Although
CD70 expression is prevalent in many tumour types, the
percentage of CD70-positive cases varies. Thus, protein expression
must be confirmed in individual tumour samples. This has been a
significant obstacle for analysis of CD70 in pathologic specimens
because most archival tissues are preserved as FFPE samples, in
which existing anti-CD70 antibodies fail to work. Earlier studies on
the expression of CD70 in cancers have relied on flow cytometric
analysis for haematologic malignancies and IHC on limited frozen
tissues for carcinomas. Our published study on renal cell carci-
nomas used the murine and humanised form of our therapeutic
anti-CD70 (1F6 mAb) as primary antibody for detection of CD70
expression in frozen tissues and, up to this point, represented
the most extensive analysis of CD70 protein expression in renal
cell carcinoma. But 1F6, similar to the commercially available
antibodies that we have tested, only gave specific binding to frozen
tissues and not FFPE samples. Similarly, our attempts to prepare
polyclonal antibodies against distinct peptides spanning most of
the extracellular and intracellular domains of CD70 also proved to
be disappointing because they tended to yield FFPE-reactive
antibodies that lacked specificity for CD70.
We overcame the obstacle of profiling CD70 in archived
specimens by generating anti-CD70 antibodies that are suitable
for detection of CD70 in FFPE tissues. Our successful approach
incorporated immunisation of denatured antigen with a novel,
high throughput screening strategy designed to identify antibodies
that specifically bound to formalin-denatured CD70. The specifi-
city of these antibodies was tested using western blot analysis and
comparative binding to known CD70-positive and -negative cell
lines as well as normal tissues. The antibodies 1C1 and 5D12
consistently showed sensitive and specific binding to CD70 in
FFPE samples of CD70-positive normal human lymphoid tissues
and tumours. In agreement with previous observations, 1C1 and
5D12 showed that expression of CD70 is limited to lymphoid
organs, in which activated T and B cells are found. Using these
reagents we were able to extensively analyse CD70 expression in
multiple tumour types. In addition, our expanded IHC analysis of
CD70 identified other indications, in which an anti-CD70 ADC
could potentially be tested, most notably a significant fraction of
pancreatic and ovarian carcinoma cases. In agreement with our
ovarian carcinoma data (Figure 3B and Table 2), CD70 has recently
been reported as a potential cisplatin resistance marker in ovarian
cancer using proteomic methods (Aggarwal et al, 2009).
We did observe discrepancy with the published literature on the
frequency of CD70 expression in nasopharyngeal and brain cancers.
Our analysis showed that 18 out of 82 cases of laryngeal and
pharyngeal cancers are positive for CD70 compared with 16 out of
20 observed by Agathanggelou et al (1995). Their study noted that
20 out of 20 of the nasopharyngeal cancers were positive for
Epstein–Barr virus (EBV). We did not examine the EBV status of
the laryngeal and pharyngeal cancers in our TMAs. However, EBV
transformation causes up-regulation of CD70 in B cells (Herbst et al,
1996) and may contribute to the higher percentage of CD70þ
nasopharyngeal cancers observed by Agathanggelou et al (1995). We
also found that only 6 out of 59 (10%) of brain cancer cases were
CD70þ, whereas Wischhusen et al (2002) found that 5 out of 12 of
glioblastomas and 3 out of 4 anaplastic astrocytomas were positive
for CD70 protein. The limited number of cases examined by
Wischhusen et al may contribute to this discordance of the data.
Our studies extend beyond a survey of CD70 in solid tumour
specimens by validating the anti-tumour activity of SGN-75 in these
indications. In preclinical studies, we have demonstrated in vitro
anti-tumour activity of the anti-CD70 antibody-drug conjugate SGN-
75 in CD70þ ovarian and pancreatic cell lines. Anti-tumour activity
of SGN-75 correlates with higher levels of CD70 expression,
suggesting that expression may be one factor that contributes to
its activity in solid tumour indications. Although the percentage of
CD70þ in pancreatic cell lines (20%) is close to what we observed in
primary pancreatic tumours (25%), the low level CD70 expression
in a pancreatic cell line (Panc-1: 10000 CD70 receptors per cell) is
not fully consistent with the expression we observed in primary
pancreatic tumours (Table 2 and Figure 3A) and it may reflect the
inability of monolayer cultures to faithfully reproduce the expression
pattern and architecture of the primary tumour (Sipos et al, 2004;
Froeling et al, 2009). Carcinoma cell lines expressing p10000 copies
of CD70 per cell did not show in vitro activity of SGN-75. In contrast,
SK-OV-3 and MiaPaCa-2/CD70 cells that have high levels of CD70
expression (Table 1), showed a potent IC50 of 29ngml
 1,w h i c h
corresponds to approximately 0.77nM delivered drug. The anti-
tumour activity of SGN-75 was highly specific and occurred at a
concentration that is well below the level required to reach saturation
binding in vitro. Furthermore, SGN-75 showed statistically signifi-
cant anti-tumour activity (P¼0.01) in mouse xenograft models of
pancreatic carcinoma when compared with the non-binding control-
treated mice. All seven mice treated with SGN-75 showed a delay in
tumour growth, whereas two of seven mice showed a complete and
sustained regression. This is the first reported study of anti-CD70
ADC anti-tumour activity in pancreatic cancer.
The targeting of CD70 by SGN-75 is thought to be driven by the
delivery of cys-mcMMAF to the tumour. However, h1F6, the
antibody backbone for SGN-75, also mediates complement-
dependent cytotoxicity and engages effector cells by Fcg receptor
to induce tumour cell lysis (McEarchern et al, 2007). The effector-
function-based activities of h1F6 are retained in the ADC
(J McEarchern and C Law, unpublished observations), suggesting
that SGN-75 has the potential to mediate anti-tumour activity in
CD70þ tumours through multiple mechanisms.
In earlier reports, we have showed SGN-75 anti-tumour in vivo
activity in models of renal cell carcinoma and NHL. The high
percentage of renal cell carcinomas and NHL samples that express
CD70 provides a strong rationale for clinical testing and a phase I
clinical trial of SGN-75 in these patient populations is currently in
progress. The results of this study support extending the clinical
study of SGN-75 to pancreatic and ovarian cancer patients with
tumours that express CD70. However, clinical testing of SGN-75 in
these malignancies must be coupled with an effective method to
prospectively evaluate the effect of variable CD70 expression on
anti-tumour activity. We are currently looking at CD70 tumour
expression on patients entering our Phase I clinical trial. It may be
possible to identify a threshold of CD70 intensity or uniformity
of expression that will allow for improved patient selection. We
believe that the results reported in this study provide a rationale
for testing CD70-directed drug delivery in new indications and
provide novel reagents for the development of screening tests.
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